Gut microbiota is associated with persistence of longer-term BNT162b2 vaccine immunogenicity

被引:0
|
作者
Ng, Ho Yu [1 ]
Liao, Yunshi [2 ]
Cheung, Ching Lung [3 ,4 ]
Zhang, Ruiqi [5 ]
Chan, Kwok Hung [6 ]
Seto, Wai-Kay [5 ]
Leung, Wai K. [5 ]
Hung, Ivan F. N. [5 ]
Lam, Tommy T. Y. [2 ,4 ,7 ]
Cheung, Ka Shing [5 ]
机构
[1] Univ Hong Kong, Li Ka Shing Fac Med, Hong Kong, Peoples R China
[2] Univ Hong Kong, Sch Publ Hlth, State Key Lab Emerging Infect Dis, Hong Kong, Peoples R China
[3] Univ Hong Kong, Queen Mary Hosp, Sch Clin Med, Dept Pharmacol & Pharm, Hong Kong, Peoples R China
[4] Lab Data Discovery Hlth Ltd, 19W Hong Kong Sci & Technol Pk, Hong Kong, Peoples R China
[5] Univ Hong Kong, Queen Mary Hosp, Sch Clin Med, Dept Med, Hong Kong, Peoples R China
[6] Univ Hong Kong, Queen Mary Hosp, Sch Clin Med, Dept Microbiol, Hong Kong, Peoples R China
[7] Ctr Immunol & Infect Ltd, 17W Hong Kong Sci & Technol Pk, Hong Kong, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2025年 / 16卷
关键词
gut microbiota; vaccine; COVID-19; vaccine immunogenicity; BNT162b2 (Pfizer-BioNTech); B-CELL MEMORY; COVID-19; VACCINE; ANTIBODY-RESPONSES; IMMUNE-RESPONSES; AMINO-ACIDS; CYSTEINE; GLUTATHIONE; METABOLITES; MODULATION; HEALTH;
D O I
10.3389/fimmu.2025.1534787
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction BNT162b2 immunogenicity wanes with time and we investigated association between gut microbiota and longer-term immunogenicity.Methods This cohort study prospectively recruited adult BNT162b2 two-dose recipients from three vaccination centers in Hong Kong. Blood samples were collected at baseline and day 180 after first dose, and tested for neutralizing antibodies (NAb) against receptor-binding domain (RBD) of wild type SARS-CoV-2 virus using chemiluminescence immunoassay. Shotgun DNA metagenomic sequencing was performed to characterize baseline stool microbiome. Baseline metabolites were measured by gas and liquid chromatography-tandem mass spectrometry (GC-MS/MS and LC-MS/MS). Primary outcome was persistent high NAb response (defined as top 25% of NAb level) at day 180. Putative bacterial species and metabolic pathways were identified using linear discriminant analysis [LDA] effect size analysis. Multivariable logistic regression adjusting for clinical factors was used to derive adjusted odds ratio (aOR) of outcome with bacterial species and metabolites.Results Of 242 subjects (median age: 50.2 years [IQR:42.5-55.6]; male:85 [35.1%]), 61 (25.2%) were high-responders while 33 (13.6%) were extreme-high responders (defined as NAb >= 200AU/mL). None had COVID-19 at end of study. Ruminococcus bicirculans (log10LDA score=3.65), Parasutterella excrementihominis (score=2.82) and Streptococcus salivarius (score=2.31) were enriched in high-responders, while Bacteroides thetaiotaomicron was enriched in low-responders (score=-3.70). On multivariable analysis, bacterial species (R. bicirculans-aOR: 1.87, 95% CI: 1.02-3.51; P. excrementihominis-aOR: 2.2, 95% CI: 1.18-4.18; S. salivarius-aOR: 2.09, 95% CI: 1.13-3.94) but not clinical factors associated with high response. R. bicirculans positively correlated with most metabolic pathways enriched in high-responders, including superpathway of L-cysteine biosynthesis (score=2.25) and L-isoleucine biosynthesis I pathway (score=2.16) known to benefit immune system. Baseline serum butyrate (aOR:10.00, 95% CI:1.81-107.2) and isoleucine (aOR:1.17, 95% CI:1.04-1.35) significantly associated with extreme-high vaccine response.Conclusion Certain gut bacterial species, metabolic pathways and metabolites associate with longer-term COVID-19 vaccine immunogenicity.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Systems vaccinology of the BNT162b2 mRNA vaccine in humans
    Arunachalam, Prabhu S.
    Scott, Madeleine K. D.
    Hagan, Thomas
    Li, Chunfeng
    Feng, Yupeng
    Wimmers, Florian
    Grigoryan, Lilit
    Trisal, Meera
    Edara, Venkata Viswanadh
    Lai, Lilin
    Chang, Sarah Esther
    Feng, Allan
    Dhingra, Shaurya
    Shah, Mihir
    Lee, Alexandra S.
    Chinthrajah, Sharon
    Sindher, Sayantani B.
    Mallajosyula, Vamsee
    Gao, Fei
    Sigal, Natalia
    Kowli, Sangeeta
    Gupta, Sheena
    Pellegrini, Kathryn
    Tharp, Gregory
    Maysel-Auslender, Sofia
    Hamilton, Sydney
    Aoued, Hadj
    Hrusovsky, Kevin
    Roskey, Mark
    Bosinger, Steven E.
    Maecker, Holden T.
    Boyd, Scott D.
    Davis, Mark M.
    Utz, Paul J.
    Suthar, Mehul S.
    Khatri, Purvesh
    Nadeau, Kari C.
    Pulendran, Bali
    NATURE, 2021, 596 (7872) : 410 - +
  • [32] Waning Immunity after the BNT162b2 Vaccine in Israel
    Goldberg, Yair
    Mandel, Micha
    Bar-On, Yinon M.
    Bodenheimer, Omri
    Freedman, Laurence
    Haas, Eric J.
    Milo, Ron
    Alroy-Preis, Sharon
    Ash, Nachman
    Huppert, Amit
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (24): : E85 - E85
  • [33] Efficacy and toxicity of BNT162b2 vaccine in cancer patients
    Ben-Aharon, I.
    Waldhorn, I.
    Holland, R.
    Peer, A.
    Halberthal, M.
    Goshen-Lago, T. G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1130 - S1130
  • [34] Sustainability of Immunogenicity of BNT162b2 Vaccine in Patients with Autoimmune Rheumatic Disease, a Retrospective Comparative Study
    Alsaed, Omar
    Chaponda, Masautso
    Satti, Eman
    Ashour, Hadil
    Almaslamani, Muna
    Al Emadi, Samar
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1574 - 1575
  • [35] Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine
    Saciuk, Yaki
    Kertes, Jennifer
    Stein, Naama Shamir
    Zohar, Anat Ekka
    JOURNAL OF INFECTIOUS DISEASES, 2022, 225 (01): : 30 - 33
  • [36] Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
    Bauernfeind, Stilla
    Salzberger, Bernd
    Hitzenbichler, Florian
    Scigala, Karolina
    Einhauser, Sebastian
    Wagner, Ralf
    Gessner, Andre
    Koestler, Josef
    Peterhoff, David
    VACCINES, 2021, 9 (10)
  • [37] Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
    Reiter, Rieke
    Von Blanckenburg, Pia
    Mutters, Reinier
    Thiemer, Julia
    Gessner, Reinhard
    Seifart, Ulf
    VACCINES, 2022, 10 (05)
  • [38] Medium-to-Long-Term Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine: A Retrospective Cohort Study
    Bianchi, Francesco Paolo
    Stefanizzi, Pasquale
    Germinario, Cinzia Annatea
    Migliore, Giovanni
    Vimercati, Luigi
    Martinelli, Andrea
    Lobifaro, Annamaria
    Diella, Giusy
    Larocca, Angela Maria Vittoria
    Tafuri, Silvio
    VACCINES, 2022, 10 (03)
  • [39] Improved immunogenicity following the third dose of BNT162b2 mRNA vaccine in heart transplant recipients
    Shaul, Aviv Avraham
    Ben Zadok, Osnat Itzhaki
    Ben-Avraham, Binyamin
    Yaari, Vicky
    Barsheshet, Alon
    Levi, Amos
    Ben Zvi, Haim
    Raz, Noa Eliakim
    Abed, Galia
    Abuhazira, Miriam
    Abu Akel, Mahmood
    Mats, Israel
    Barac, Yaron D.
    Aravot, Dan
    Kornowski, Ran
    Ben-Gal, Tuvia
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2022, 62 (04)
  • [40] Acute myocarditis following administration of BNT162b2 vaccine
    Habib, Mhd Baraa
    Hamamyh, Tahseen
    Elyas, Ahmed
    Altermanini, Mohammed
    Elhassan, Mawahib
    IDCASES, 2021, 25